Lack of association of genetic polymorphisms of angiotensin-converting enzyme gene i/d and glutathione-s-transferase enzyme t1 and m1 with retinopathy of prematures

Genetics and Molecular Research

Volumn 9, Issue 4, 2010, Pages 2131-2139

  Yildiz, M ^a   Karkucak, M ^a   Yakut, T ^a   Gorukmez, O ^a   Ozmen, A ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

Ace gene; Gstm1; Gstt1; Polymorphism; Retinopathy of prematurity

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1;

AGAR GEL ELECTROPHORESIS; ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MULTIPLEX POLYMERASE CHAIN REACTION; RETROLENTAL FIBROPLASIA;

EID: 78149441001     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/vol9-4gmr887     Document Type: Article

References (34)

1. Abbas A, Delvinquiere K, Lechevrel M, Lebailly P, et al. (2004). GSTM1, GSTT1, GSTP1 and CYP1A1 genetic polymorphisms and susceptibility to esophageal cancer in a French population: different pattern of squamous cell carcinoma and adenocarcinoma. World J. Gastroenterol. 10: 3389-3393.
2. Balogh A, Derzbach L, Vannay A and Vásárhelyi B (2006). Lack of association between insulin-like growth factor I receptor G (+3174)A polymorphism and retinopathy of prematurity. Graefes Arch. Clin. Exp. Ophthalmol. 244: 1035-1038.
3. Bányász I, Bokodi G, Vannay A, Szebeni B, et al. (2006). Genetic polymorphisms of vascular endothelial growth factor and angiopoietin 2 in retinopathy of prematurity. Curr. Eye Res. 31: 685-690.
4. Barceló A, Elorza MA, Barbé F, Santos C, et al. (2001). Angiotensin converting enzyme in patients with sleep apnoea syndrome: plasma activity and gene polymorphisms. Eur. Respir. J. 17: 728-732.
5. Beneteau-Burnat B and Baudin B (1991). Angiotensin-converting enzyme: clinical applications and laboratory investigations on serum and other biological fluids. Crit. Rev. Clin. Lab. Sci. 28: 337-356.
6. Bossi E and Koerner F (1995). Retinopathy of prematurity. Intensive Care Med. 21: 241-246.
7. Habdous M, Siest G, Herbeth B, Vincent-Viry M, et al. (2004). Glutathione S-transferases genetic polymorphisms and human diseases: overview of epidemiological studies. Ann. Biol. Clin. 62: 15-24.
8. Haider MZ, Devarajan LV, Al-Essa M, Srivastva BS, et al. (2000). Missense mutations in norrie disease gene are not associated with advanced stages of retinopathy of prematurity in Kuwaiti arabs. Biol. Neonate 77: 88-91.
9. Haider MZ, Devarajan LV, Al-Essa M, Srivastva BS, et al. (2001). Retinopathy of prematurity: mutations in the Norrie disease gene and the risk of progression to advanced stages. Pediatr. Int. 43: 120-123.
10. Haider MZ, Devarajan LV, Al-Essa M and Kumar H (2002). Angiotensin-converting enzyme gene insertion/deletion polymorphism in Kuwaiti children with retinopathy of prematurity. Biol. Neonate 82: 84-88.
11. Hayes JD, Flanagan JU and Jowsey IR (2005). Glutathione transferases. Annu. Rev. Pharmacol. Toxicol. 45: 51-88.
12. Hayes LW, Goguen CA, Ching SF and Slakey LL (1978). Angiotensin-converting enzyme: accumulation in medium from cultured endothelial cells. Biochem. Biophys. Res. Commun. 82: 1147-1153.
13. Hutcheson KA, Paluru PC, Bernstein SL, Koh J, et al. (2005). Norrie disease gene sequence variants in an ethnically diverse population with retinopathy of prematurity. Mol. Vis. 11: 501-508.
14. Karna P, Muttineni J, Angell L and Karmaus W (2005). Retinopathy of prematurity and risk factors: a prospective cohort study. BMC Pediatr. 5: 18.
15. Kwinta P, Bik-Multanowski M, Mitkowska Z, Tomasik T, et al. (2008). The clinical role of vascular endothelial growth factor (VEGF) system in the pathogenesis of retinopathy of prematurity. Graefes Arch. Clin. Exp. Ophthalmol. 246: 1467-1475.
16. Lee YJ and Tsai JC (2002). ACE gene insertion/deletion polymorphism associated with 1998 World Health Organization definition of metabolic syndrome in Chinese type 2 diabetic patients. Diabetes Care 25: 1002-1008.
17. Ng YK, Fielder AR, Shaw DE and Levene MI (1988). Epidemiology of retinopathy of prematurity. Lancet 2: 1235-1238.
18. Nishimura H, Tsuji H, Masuda H, Kasahara T, et al. (1999). The effects of angiotensin metabolites on the regulation of coagulation and fibrinolysis in cultured rat aortic endothelial cells. Thromb. Haemost. 82: 1516-1521.
19. Onaran I, Ozaydin A, Ozdas SB and Ulutin T (2000a). Inhibition of platelet function by GSTM1-null human peripheral lymphocytes exposed to benzo(a)pyrene-induced challenge. Cell Biol. Toxicol. 16: 313-323.
20. Onaran I, Ozaydin A, Akbas F, Gultepe M, et al. (2000b). Are individuals with glutathione S-transferase GSTT1 null genotype more susceptible to in vitro oxidative damage? J. Toxicol. Environ. Health A 59: 15-26.
21. Rusai K, Vannay A, Szebeni B, Borgulya G, et al. (2008). Endothelial nitric oxide synthase gene T-786C and 27-bp repeat gene polymorphisms in retinopathy of prematurity. Mol. Vis. 14: 286-290.
22. Shah VA, Yeo CL, Ling YL and Ho LY (2005). Incidence, risk factors of retinopathy of prematurity among very low birth weight infants in Singapore. Ann. Acad. Med. Singapore 34: 169-178.
23. Shastry BS (2007). Assessment of the contribution of insulin-like growth factor I receptor 3174 G→A polymorphism to the progression of advanced retinopathy of prematurity. Eur. J. Ophthalmol. 17: 950-953.
24. Shastry BS (2009). Lack of association of VEGF (-2578 C→A) and ANG 2 (-35 G→C) gene polymorphisms with the progression of retinopathy of prematurity. Graefes Arch. Clin. Exp. Ophthalmol. 247: 859-860.
25. Shastry BS and Qu X (2007). Lack of association of the VEGF gene promoter (-634 G→C and -460 C→T) polymorphism and the risk of advanced retinopathy of prematurity. Graefes Arch. Clin. Exp. Ophthalmol. 245: 741-743.
26. Shastry BS, Pendergast SD, Hartzer MK, Liu X, et al. (1997). Identification of missense mutations in the Norrie disease gene associated with advanced retinopathy of prematurity. Arch. Ophthalmol. 115: 651-655.
27. Smith LE (2002). Pathogenesis of retinopathy of prematurity. Acta Paediatr. 91: 26-28.
28. Strange RC, Spiteri MA, Ramachandran S and Fryer AA (2001). Glutathione-S-transferase family of enzymes. Mutat. Res. 482: 21-26.
29. Subhani M, Combs A, Weber P, Gerontis C, et al. (2001). Screening guidelines for retinopathy of prematurity: the need for revision in extremely low birth weight infants. Pediatrics 107: 656-659.
30. Uzunoǧlu S, Acar H, Okudan N, Gökbel H, et al. (2006). Evaluation of the association between null genotypes of glutathione-S-transferases and Behcet's disease. Arch. Dermatol. Res. 297: 289-293.
31. Van der Hel OL, Peeters PH, Hein DW, Doll MA, et al. (2003). NAT2 slow acetylation and GSTM1 null genotypes may increase postmenopausal breast cancer risk in long-term smoking women. Pharmacogenetics 13: 399-407.
32. Vaughan DE (1997). The renin-angiotensin system and fibrinolysis. Am. J. Cardiol. 79: 12-16.
33. Yaggi HK, Concato J, Kernan WN, Lichtman JH, et al. (2005). Obstructive sleep apnea as a risk factor for stroke and death. N. Engl. J. Med. 353: 2034-2041.
34. Zhong SL, Zhou SF, Chen X, Chan SY, et al. (2006). Relationship between genotype and enzyme activity of glutathione S-transferases M1 and P1 in Chinese. Eur. J. Pharm. Sci. 28: 77-85.